Introduction {#s1}
============

Pulmonary function is usually assessed by measurement of forced expiratory volume in one second (FEV~1~), forced vital capacity (FVC), and the ratio of FEV~1~ to FVC. The measurements are integral to the diagnosis of chronic obstructive pulmonary disease (COPD), and also are important long term predictors of population morbidity and mortality [@pone.0019382-Schunemann1]. Reduced FEV~1~/FVC defines airways obstruction; whereas reduced FEV~1~ grades the severity of obstruction [@pone.0019382-Rabe1].

Pulmonary function is determined by both environmental and genetic factors. Tobacco smoking is the major environmental risk factor for the development of COPD. A genetic contribution to pulmonary function is well established with heritability estimates reaching 77 percent for FEV~1~ [@pone.0019382-Hubert1]. Linkage analyses within families have previously identified multiple genomic regions associated with spirometry measures and respiratory diseases. In addition, candidate gene studies have identified more than 100 genes which have been suggested to contribute to variability in lung function. The majority have been studied because of their potential pathophysiological role in the development of COPD. Some genes have been examined for association with lung function measurements in individuals with other specific respiratory diseases (most commonly asthma), or to a lesser extent, in the general population. With the exception of *SERPINA1*, which is the best documented genetic risk factor to influence the development of COPD [@pone.0019382-Laurell1], these genes have not shown consistent associations across different studies [@pone.0019382-Hersh1], [@pone.0019382-Smolonska1].

Recently, we established the SpiroMeta consortium and published a large collective meta-analysis of lung function genome-wide association studies (GWAS) in 20,288 individuals of European origin, with follow-up of top SNPs in a further 54,276 individuals [@pone.0019382-Repapi1], [@pone.0019382-Hancock1]. Our study confirmed the hedgehog interacting protein (*HHIP*) association previously published [@pone.0019382-Wilk1], [@pone.0019382-Pillai1] and identified five new loci associated with FEV~1~ or FEV~1~/FVC ratio including tensin 1 gene (*TNS1*), glutathione S-transferase, C-terminal domain containing (*GSTCD*), 5-hydroxytryptamine receptor 4 (*HTR4*), advanced glycosylation end product-specific receptor (*AGER*), and thrombospondin, type I, domain containing 4 (*THSD4*). A study with similar design by the CHARGE consortium also identified *HHIP*, *AGER*, *HTR4*, and *GSTCD*, and in addition suggested a potential role of five additional genes (G protein-coupled receptor 126 (*GPR126*), a disintegrin and metalloproteinase domain 19 (*ADAM19*), family with sequence similarity 13, member A (*FAM13A*), patched homolog 1 (*PTCH1*), and phosphotyrosine interaction domain containing (*PID1*) [@pone.0019382-Hancock1].

The identification of these genes offers potential insight into the pathophysiology of altered lung function. The SpiroMeta consortium provides a powerful resource in which to study genetic associations with lung function. We aimed to comprehensively evaluate whether genes studied in candidate gene or small genome-wide association studies, and reported to be associated with lung function or COPD in these studies, were associated with lung function measures in this large general population sample.

Results {#s2}
=======

Literature search {#s2a}
-----------------

The literature search identified 1719 publications. Of these, 104 reported one or more genetic associations: these are listed in [text S1](#pone.0019382.s004){ref-type="supplementary-material"} in the online supporting information. These publications varied according to their study designs and the populations studied. 47 papers reported association with COPD using case control or family based designs. The remaining literature reported association with lung function traits within populations with specific respiratory diseases (asthma (26) and COPD (17)), or in general population cohorts (14). Nine publications studied other populations which included patients with cystic fibrosis (2), *SERPINA1* deficiency (2), cotton and grain workers (2), lung cancer (1), fire fighters (1) and post myocardial infarction (MI) patients (1). Some papers reported more than one endpoint.

These 104 relevant publications identified 130 genes and 48 intergenic SNPs. We investigated association between FEV~1~ and FEV~1~/FVC and each of the 16,936 genotyped and imputed SNPs spanning these regions in the SpiroMeta dataset.

Contribution of all tested genes to lung function measures in SpiroMeta {#s2b}
-----------------------------------------------------------------------

Quantile-quantile (Q-Q) plots did not show large deviations between observed and expected P values for FEV~1~ and FEV~1~/FVC in all participants and for FEV~1~/FVC in ever-smokers ([Figure 1](#pone-0019382-g001){ref-type="fig"}). The plot of FEV~1~ in ever-smokers, however, shows slight deviations for high signal SNPs. The genomic inflation factor, λ for FEV~1~ is 0.83 in all individuals and 1.05 in smokers; λ for FEV~1~/FVC in all individuals is 0.92 and 1.13 in smokers.

![Quantile-quantile (Q-Q) plots of association results for FEV~1~ and FEV~1~/FVC.\
The Q-Q plot of association is shown for all individuals in Panel A, and separately for ever-smokers only in panel B. Q-Q plots compare the observed P values (obs.p) to expected P values (exp.p) on the logarithmic scale under the null hypothesis of no significant association. λ: Lambda.](pone.0019382.g001){#pone-0019382-g001}

Using the Bonferroni corrected P value threshold of 1.3×10^−5^, none of the tested SNPs demonstrated significant association with either FEV~1~ or FEV~1~/FVC.

Association results in all individuals {#s2c}
--------------------------------------

In order to examine possible signals in greater detail, we also explored region plots for the top SNPs identified (SNPs with the lowest P values). The three top loci with the most significant P values for all regions tested in all individuals are presented in [table 1](#pone-0019382-t001){ref-type="table"}.

10.1371/journal.pone.0019382.t001

###### Association results for the three most significantly associated loci.

![](pone.0019382.t001){#pone-0019382-t001-1}

  Gene                                 Locus         SNP       SNP function   coded allele   Coded allele frequency   N eff    Beta     Se          P
  -------------------------------- ------------- ------------ -------------- -------------- ------------------------ ------- -------- ------- -------------
  **FEV~1~ All individuals**                                                                                                                  
  ***MACROD2***                       20p12.1      rs204652       Intron           G                 0.983            13551   −0.187   0.047   6.81×10^−5^
  ***CNTN5***                       11q21-q22.2   rs17133553      Intron           T                 0.966            13669   −0.100   0.029   4.37×10^−4^
  ***MTHFD1L***                       6q25.1       rs803450       Intron           G                 0.625            18497   0.036    0.011   1.03×10^−3^
  **FEV~1~ Smokers**                                                                                                                          
  ***SERPINA1***                     14q32.13     rs3748312       Intron           T                 0.167            9338    0.085    0.022   8.41×10^−5^
  ***PDE4D***                          5q12        rs298028       Intron           T                 0.283            10829   −0.069   0.018   1.22×10^−4^
  ***MACROD2***                       20p12.1      rs204652       Intron           G                 0.983            6872    −0.251   0.067   1.67×10^−4^
  **FEV~1~/FVC All individuals**                                                                                                              
  ***ABCC1***                         16p13.1     rs3887893       Intron           T                 0.625            15509   −0.043   0.012   4.38×10^−4^
  ***ESR1***                          6q25.1      rs11155818      Intron           G                 0.992            12571   0.185    0.053   5.02×10^−4^
  ***CNTN5***                       11q21-q22.2   rs1216170       Intron           C                 0.284            18863   0.039    0.011   6.02×10^−4^
  **FEV~1~/FVC Smokers**                                                                                                                      
  ***ESR1***                          6q25.1      rs9322335       Intron           T                 0.217            9495    −0.061   0.018   5.42×10^−4^
  ***RHBDD1***                        2q36.3      rs1864271       Intron           G                 0.708            7385    0.066    0.019   6.40×10^−4^
  ***MTHFD1L***                       6q25.1      rs1738567       Intron           C                 0.367            10668   0.046    0.014   1.33×10^−3^

The table shows the three most significant loci associated with FEV~1~ and FEV~1~/FVC ratio in all individuals and ever-Smokers. N eff: the effective sample size. Beta: regression coefficient on a transformed scale. Se: standard error. P: *P* value. Coded allele frequency based on HapMap Release 24. *MACROD2:* MACRO domain containing 2. *CNTN5:* Contactin 5. *MTHFD1L* Methylenetetrahydrofolate dehydrogenase (NADP+ dependent) 1-like. *SERPINA1:* serpin peptidase inhibitor, clade A, member 1 (alpha-1 antitrypsin *AAT*). *PDE4D*: Phosphodiesterase 4D, cAMP-specific (phosphodiesterase E3 dunce homolog, Drosophila). *ABCC1*: ATP-binding cassette, sub-family C, member 1. *ESR1*: estrogen receptor 1. *RHBDD1*: rhomboid domain containing 1.

Among all individuals, the strongest association with FEV~1~ was with rs204652 in MACRO domain containing 2 (*MACROD2*) on chromosome 20. SNP rs17133553 in Contactin 5 (*CNTN5*) on chromosome 11 was the second top locus for association with FEV~1~ and third for FEV~1~/FVC ratio. SNP rs803450 in Methylenetetrahydrofolate dehydrogenase (NADP+ dependent) 1-like (*MTHFD1L*) on chromosome 6 showed association with FEV~1~ in all individuals. For FEV~1~/FVC ratio in all individuals the strongest association was with rs3887893 in ATP-binding cassette, sub-family C, member 1 (*ABCC1*) on chromosome 16, the second strongest signal was for rs11155818 in estrogen receptor 1(*ESR1*) on chromosome 6.

The region association plots around the most significant SNPs associated with FEV~1~ and FEV~1~/FVC in all individuals provide little evidence from supporting SNPs to suggest strong regions of association in *MACROD2*, *CNTN5*, *MTHFD1L*, and *ESR1*, and *ABCC1* in these data (See [figure S1](#pone.0019382.s001){ref-type="supplementary-material"} in the online supporting information).

Association results in ever-smokers {#s2d}
-----------------------------------

To study the impact of smoking on potential genetic associations with lung function, we repeated the analysis restricted to individuals who had ever smoked (ever-smokers). The most significant loci identified are shown in [table 1](#pone-0019382-t001){ref-type="table"}.

Among ever-smokers, rs3748312 in serpin peptidase inhibitor, clade A, member 1 (*SERPINA1*) on chromosome 14, also known as alpha-1 antitrypsin (*AAT*) showed the strongest association with FEV~1~. SNP rs298028 in Phosphodiesterase 4D, cAMP-specific (phosphodiesterase E3 dunce homolog, Drosophila) (*PDE4D*) on chromosome 5 showed the second strongest association with FEV1, followed by MACROD2.

The strongest association with FEV1/FVC ratio among smokers was observed with rs9322335 in 1(*ESR1*) on chromosome 6. The second strongest association was rs1864271 in with rhomboid domain containing 1 (*RHBDD1*) on chromosome 2, followed by rs1738567 in (*MTHFD1L*) on chromosome 6. The region association plots for *SERPINA1* and *PDE4D* among ever-smokers ([figure 2](#pone-0019382-g002){ref-type="fig"}) show some supportive evidence for the association of these two loci. The region association plots for the additional loci among ever-smokers reported in [table 1](#pone-0019382-t001){ref-type="table"} are shown in [figure S2](#pone.0019382.s002){ref-type="supplementary-material"} in the online supporting information.

![Regional association plots for *SERPINA1* (A) and *PDE4D* among ever-smokers (B) in SpiroMeta.\
Statistical significance of each SNP on the −log10 scale as a function of chromosome position (NCBI build 36). The sentinel SNP at each locus is shown in blue; the correlations (*r* ^2^) of each of the surrounding SNPs to the sentinel SNP are shown in the indicated colours. The relevant trait (FEV~1~ or FEV~1~/FVC ratio) is indicated for each plot. Recombination rate is shown in pale blue.](pone.0019382.g002){#pone-0019382-g002}

Association results excluding loci identified in previous GWAS {#s2e}
--------------------------------------------------------------

Because some of the regions identified were observed in the previously published small GWAS studies included in our literature search, we also present the top three genes for the relevant end points after excluding GWAS hits ([Table 2](#pone-0019382-t002){ref-type="table"}).

10.1371/journal.pone.0019382.t002

###### Association results for the most significant loci excluding genes identified in GWAS.

![](pone.0019382.t002){#pone-0019382-t002-2}

  gene                       locus        SNP       SNP function   coded allele   Coded allele Frequency   N eff    Beta     se          P
  ------------------------ ---------- ------------ -------------- -------------- ------------------------ ------- -------- ------- -------------
  **FEV~1~ All**                                                                                                                   
  ***PDE4D***                 5q12      rs172362       Intron           C                 0.133            18929   −0.048   0.015   1.36×10^−3^
  ***TRPV4***               12q24.1    rs3742030      Missense          G                 0.992            17591   −0.110   0.035   1.58×10^−3^
  ***NAT2***                  8p22     rs6988857     Intergenic         T                 0.241            20080   0.035    0.011   2.37×10^−3^
  **FEV~1~ Smokers**                                                                                                               
  ***SERPINA1***            14q32.13   rs3748312       Intron           T                 0.167            9338    0.085    0.022   8.41×10^−5^
  ***PDE4D***                 5q12      rs298028       Intron           T                 0.283            20829   −0.069   0.018   1.22×10^−4^
  ***BCL2***                18q21.3    rs2850760       Intron           T                 0.425            10888   0.050    0.014   4.66×10^−4^
  **FEV~1~/FVC All**                                                                                                               
  ***ABCC1***               16p13.1    rs3887893       Intron           T                 0.625            15509   −0.043   0.012   4.38×10^−4^
  ***ESR1***                 6q25.1    rs11155818      Intron           G                 0.992            12571   0.185    0.053   5.02×10^−4^
  ***AIF1***                 6p21.3    rs3132451    5′near gene         G                 0.883            19889   0.045    0.014   7.84×10^−4^
  **FEV~1~/FVC Smokers**                                                                                                           
  ***ESR1***                 6q25.1    rs9322335       Intron           T                 0.217            9495    −0.061   0.018   5.42×10^−4^
  ***ABCC1***               16p13.1    rs3887893       Intron           T                 0.625            8156    −0.054   0.017   1.36×10^−3^
  ***CD22***                19q13.1    rs7251526       Intron           T                 0.246            8328    −0.054   0.018   2.00×10^−3^

The table shows association results for the three most significant loci associated with FEV~1~ and FEV~1~/FVC, in all individuals and in ever-smokers after excluding genes identified in GWAS. N eff: the effective sample size. Beta: regression coefficient on a transformed scale. Se: standard error. P: P value. Coded allele frequency based on HapMap Release 24. *PDE4D*: Phosphodiesterase 4D, cAMP-specific (phosphodiesterase E3 dunce homolog, Drosophila). *TRPV4:* transient receptor potential cation channel, subfamily V, member 4. *NAT2:* N-acetyltransferase 2. *SERPINA1:* serpin peptidase inhibitor, clade A, member 1 (alpha-1 antitrypsin *AAT*). *BCL2:* B-cell CLL/lymphoma 2. *ABCC1*: ATP-binding cassette, sub-family C, member 1. *AIF1:* allograft inflammatory factor 1. *ESR1*: estrogen receptor 1. *CD22:* cluster of differentiation; CD22 molecule.

The additional genes identified in this analysis for association with FEV~1~ among all individuals were the transient receptor potential cation channel, subfamily V, member 4 (*TRPV4*) on chromosome 12, and N-acetyltransferase 2 (*NAT2*) on chromosome 8. Among ever-smokers, association results for FEV~1~ identified B-cell CLL/lymphoma 2 (*BCL2*) on chromosome 18. Association results for FEV~1~/FVC ratio identified allograft inflammatory factor 1(*AIF1*) on chromosome 6 among all individuals, and cluster of differentiation; CD22 molecule (*CD22*) on chromosome 19 among ever-smokers. The region association plots for the most significant loci in [table 2](#pone-0019382-t002){ref-type="table"} and not presented earlier are shown in [figure S3](#pone.0019382.s003){ref-type="supplementary-material"} in the online supporting information. The plots show some additional support for all presented loci except for *ABCC1* among ever-smokers.

Discussion {#s3}
==========

In the SpiroMeta study, we generated a comprehensive dataset to analyse associations between genetic variants and lung function in the general population [@pone.0019382-Repapi1]. There have been many small previous studies, mostly of individual candidate genes examining association with lung function, which have produced conflicting results. Therefore, in this paper, we undertook a comprehensive literature review to identify relevant gene regions and analysed potential associations with FEV~1~ and FEV~1~/FVC ratio in all individuals within SpiroMeta. In addition, given the impact of smoking on lung function, we also analysed the associations separately in ever-smokers. There were no strong association signals in never-smokers group (data available on request).

The main conclusion from this study is that, within 178 previously reported regions, we found no SNP associations which exceeded the significance threshold (P\<1.3×10^−5^) we employed after correction for multiple testing. Our results suggest these regions do not constitute major genetic determinants of lung function measures at the general population level. The lack of replication and sometimes contradicting results in previous studies may reflect the fact that many previously reported associations came from studies with small sample sizes, possibly leading to false positive results.

Despite the failure to identify any overall significant contribution of a single SNP from previously reported genes to lung function, there are some potentially interesting signals apparent from the region plots suggesting that there may be a small signal from variants in some of the genes of interest.

*SERPINA1* showed the strongest association with FEV~1~ among smokers (8.41×10^−5^). It encodes alpha-1 Antitrypsin protein (AAT), mainly produced in the liver and has the primary role of inhibiting neutrophil elastase in the lungs [@pone.0019382-Kalsheker1]. Protein variants of this gene have been classified based on their migration in an isoelectric pH gradient from A to Z. Among Caucasians, the M allele is the most common allele with six subtypes: M1--M6 with allele frequencies greater than 95 percent and associated with normal AAT levels. The common deficiency variants; S (frequency 0.02--0.03) and Z (frequency 0.01--0.03), are associated with mild and severe reductions in serum AAT levels, respectively [@pone.0019382-Kalsheker1], [@pone.0019382-DeMeo1]. The *r* ^2^ between the Z allele rs28929474 and rs3748312 is 0.08 (based on 1000 Genomes Project pilot 1 data from 120 CEU individuals). Our top SNP, rs3748312, is in LD (*r* ^2^ = 0.603) with the M1 allele SNP rs6647, but is in very weak LD with M2 rs709932 (*r* ^2^ = 0.033) and M3 rs1303 (*r* ^2^ = 0.051). The S allele SNP rs45551939 (merged into rs17580) was not found in HapMap (version24). It is possible that the signal observed in our data is due to variants with effects on gene expression and/or protein levels, and this idea is supported by a previous study showing novel variants in *SERPINA1* to be associated with increased susceptibility to COPD independently of the Z allele [@pone.0019382-Chappell1]. The relatively strong signal observed in our study suggests a possible role for variants in *SERPINA1* in smokers at the general population level beyond that observed in carriers of known deficient alleles.

The *PDE4D* gene encodes the type 4D phosphodiesterase, which degrades cyclic adenosine monophosphate (cAMP), an important signal transduction molecule in all cell types. Polymorphisms within *PDE4D* have been associated with stroke [@pone.0019382-Gretarsdottir1], and bone mineral density [@pone.0019382-Reneland1]. *PDE4D* is the most dominant phosphodiesterase in the lungs and plays an important role in regulating airway smooth muscle contractility [@pone.0019382-Mehats1] demonstrated by *PDE4D* knockout mice lacking response to methacholine [@pone.0019382-Hansen1]. A study in a Japanese population reported association of one *PDE4D* SNP (rs829259) and a haplotype consisting of rs10075508 and one interleukin 13 (*IL13*) SNP with COPD [@pone.0019382-Homma1]. SNP rs829259 was not associated with FEV~1~ in all individuals (P = 0.68) and in smokers (P = 0.21) in our study, and SNP rs10075508 was not genotyped or imputed in SpiroMeta. A recent GWAS has also identified *PDE4D* as an asthma susceptibility gene [@pone.0019382-Himes1], however, none of the top 5 SNPs associated with asthma is present in our dataset, and the linkage disequilibrium (LD) with SNPs in SpiroMeta is low, so it is difficult to comment on their contribution to lung function measures in our study.

Our study has a number of strengths. First, we have power to detect associations of small magnitude, with data on 20,288 individuals from 14 European studies with more than 2.5 million genotyped and imputed SNPs. Second, we aimed to minimise Type 1 error whilst taking appropriate account of the correlation between neighbouring SNPs. Finally, the literature search was designed to be comprehensive to include all reported genetic variants with effect on lung function irrespective of disease status or ethnicity. To our knowledge, this is the first study to comprehensively evaluate the role of previously associated genes in a large genome-wide association study.

However, it is important to recognise the limitations of our study. We have tested for association in a general population sample; the magnitude of effect of these genetic variants may be greater in populations enriched with individuals with respiratory diseases such as asthma and COPD. Second, we have tested with cross sectional lung function measures. Some of the variants tested might affect longitudinal changes by accelerating or decelerating the decline in lung function, although this would still be expected to result in effects evident in cross sectional data. Third, the power of our study to detect associations of SNPs with modest effect sizes on lung function was limited given our relatively conservative approach to multiple testing, therefore we cannot rule out a real but modest effect of some of these loci on lung function and susceptibility to respiratory diseases in the general population. Alternative approaches could be to utilise a priori evidence about the reported direction of effect and a priori assumptions about the likely presence of multiple causal variants. Fourth, we tested for association with lung function measures among individuals of European ancestry, and the contribution of these variants to lung function in other populations may vary. Finally, the coverage of tested genetic regions varies depending on the genome-wide arrays used and imputation quality metrics.

In conclusion, we have shown that none of the SNPs tagging the genes previously reported to determine lung function were significantly associated with FEV~1~ or FEV~1~/FVC ratio in the SpiroMeta general population study. We found some evidence to suggest a possible contribution for the *SERPINA1* and *PDE4D* loci to lung function in smokers which warrant further study. As a resource to the scientific community we have provided the complete association results ([Dataset S1](#pone.0019382.s005){ref-type="supplementary-material"}) in the online supporting information.

Methods {#s4}
=======

Systematic Literature search {#s4a}
----------------------------

We conducted a literature search in PubMed in October 2009 for genetic association studies of lung function measurements and/or COPD. The search terms used were: "Lung function" OR "pulmonary function" OR "FEV~1~" OR "FEV~1~/FVC" OR "Forced Expiratory Volume" OR "Forced Vital Capacity" OR "ASTHMA" OR "COPD" OR "BRONCHIAL HYPERRESPONSIVENESS" OR "BHR" OR "obstructive lung disease" AND "SNP" OR "single nucleotide polymorphism" OR "polymorphism" OR "gene" OR "genetic" OR "genom\*" OR "variation" AND "Linkage" OR "association"

From the search results, we included relevant papers reporting only positive association results. For the three GWAS papers identified, we took a more inclusive approach and included all loci presented in the publication body, and not just those meeting genome-wide significance. We excluded papers reporting associations with respiratory diseases (e.g. asthma) without association with lung function measurements.

Statistical analysis {#s4b}
--------------------

The genes and intergenic SNPs identified in the relevant literature were evaluated in the SpiroMeta dataset using an extended region of +/−10 kilobases (kb) from the gene coordinates downloaded from the UCSC genome browser (we used the SNP coordinate +/−10 kb for intergenic SNPs). Meta-analysis association results for SNPs in these (+/−10 kb extended) regions were extracted from the SpiroMeta dataset for both FEV~1~ and FEV~1~/FVC in all individuals and separately in ever--smokers. The complete cohort descriptions, study design and methods have been previously reported [@pone.0019382-Repapi1], but we provide here a brief summary. At study level, non-genotyped SNPs were imputed using standard approaches [@pone.0019382-Homma1], [@pone.0019382-Marchini1] to facilitate meta-analysis of studies employing different genotyping platforms. Thus up to 2,705,257 SNPs were tested for association with FEV1 and FEV1/FVC using additive models and adjusting for age, sex, height and ancestry principal components. Then, the results were meta-analysed across studies using inverse variance weighting. Genomic control was applied at the study level and after the meta-analysis to correct for test inflation due to population stratification [@pone.0019382-Devlin1]. We excluded SNPs which were not well measured or imputed in the study (identifiable by an "effective sample size" of \<50% of the total sample size) [@pone.0019382-Repapi1]. In all, we identified 16,936 genotyped and imputed SNPs in the gene and intergenic regions described above which met our inclusion criteria.

In order to correct for multiple testing of SNPs in linkage disequilibrium we used Li and Ji\'s [@pone.0019382-Li1] method for calculating the effective number of independent tests from pairwise SNP correlations. Pairwise SNP correlations were obtained from reference genotypes of 1468 subjects in the Busselton study [@pone.0019382-Palmer1]. We estimated that the association tests for the 16,936 highly correlated SNPs we selected in the regions of interest equated to 3,891 independent tests.

To maintain a Type 1 error rate of 5%, we adjusted the significance threshold using a Bonferroni correction (0.05/3891). Thus a threshold of 1.3×10^−5^ was used to determine statistical significance.

Supporting Information {#s5}
======================

###### 

Regional association plots of the most significant lung function--associated loci among all individuals in SpiroMeta (A--F). Statistical significance of each SNP on the −log10 scale as a function of chromosome position (NCBI build 36). The sentinel SNP at each locus is shown in blue; the correlations (*r* ^2^) of each of the surrounding SNPs to the sentinel SNP are shown in the indicated colours. The relevant trait (FEV~1~ or FEV~1~/FVC ratio) is indicated for each plot. Recombination rate is shown in pale blue.
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Click here for additional data file.

###### 

Regional association plots of the most significant lung function--associated loci among ever-smokers in SpiroMeta (A--D). Statistical significance of each SNP on the −log10 scale as a function of chromosome position (NCBI build 36). The sentinel SNP at each locus is shown in blue; the correlations (*r* ^2^) of each of the surrounding SNPs to the sentinel SNP are shown in the indicated colours. The relevant trait (FEV~1~ or FEV~1~/FVC ratio) is indicated for each plot. Recombination rate is shown in pale blue.
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###### 

Click here for additional data file.

###### 

Regional association plots of the most significant lung function--associated loci (A--G) after excluding genes identified in GWAS. Statistical significance of each SNP on the −log10 scale as a function of chromosome position (NCBI build 36). The sentinel SNP at each locus is shown in blue; the correlations (*r* ^2^) of each of the surrounding SNPs to the sentinel SNP are shown in the indicated colours. The relevant trait (FEV~1~ or FEV~1~/FVC ratio) and whether it is in all individuals or ever-smokers is indicated for each plot. Recombination rate is shown in pale blue.

(TIF)
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Click here for additional data file.
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The 104 relevant publications identified in the literature search.
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Complete FEV~1~ and FEV~1~/FVC association results for all individuals and separately for ever-smokers.
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Click here for additional data file.
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